The challenge
The client needed to determine which of roughly 20 candidate molecular targets and pathways offered the most promise, and how best to act on that prioritization through partnership, minority investment, or outright acquisition.
The solution
BCE conducted a literature review of the top 20 pathways, scoring each against a defined set of criteria including linked disease areas, number of actionable targets, and quality of supporting evidence. BCE then went deeper on the top 10 pathways, prioritizing them against the oncology markets of greatest interest to the client, and recommended specific companies for corporate venture investment or outright acquisition.
The results
BCE identified multiple top-tier targets for the client. The client has since grown its immunotherapy portfolio substantially through partnerships that came out of this work.
